Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.44 |
| ▸ | HTR2A | P28223 | 9/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6076450 | 0.81 | ADRA2A (0.38) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL6077356 | 0.80 | ADRA2A (0.37) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL6076954 | 0.80 | DDR1 (0.39) | SLC6A4SLC6A2SLC6A3ADRA2AADRA2B | |
| SCHEMBL17689059 | 0.79 | DDR1 (0.39) | SLC6A4SLC6A2SLC6A3ADRA2AADRA2B | |
| SCHEMBL21227644 | 0.78 | SLC6A4 (0.50) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL2526394 | 0.77 | MPO (0.41) | SLC6A4SLC6A2SLC6A3ADRA2AADRA2B | |
| SCHEMBL2095744 | 0.76 | SLC6A4 (0.49) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL14613818 | 0.75 | SLC6A4 (0.51) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| SCHEMBL21494282 | 0.75 | SLC6A4 (0.47) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 | |
| Hydrochloric Acid SCHEMBL29289846 | 0.75 | IDO1 (0.50) | SLC6A4HTR2AKCNH2SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109186-B2 | 4-hydroxy-5-oxo-1-(2-[4-methylpiperazin-1-yl]ethyl)-2,5-dihydro-1H-pyrrole-3-carboxylic acid (3,4-dichlorobenzyl)-methyl-amide for human immunodeficiency virus (HIV) treatment | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040110804-A1 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| WO-2004004657-A2 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110804-A1 | HIV integrase inhibitors | CDKN1A, SAMHD1, CTCF | SLC6A4 4141/4885HTR2A 4648/4885KCNH2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.